Differing associations between Aβ accumulation, hypoperfusion, blood–brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer's disease

Abstract

Recent studies implicate loss of pericytes in hypoperfusion and blood–brain barrier (BBB) leakage in Alzheimer's disease (AD). In this study, we have measured levels of the pericyte marker, platelet-derived growth factor receptor-β (PDGFRB), and fibrinogen (to assess blood–brain barrier leakage), and analyzed their relationship to indicators of microvessel density (von Willebrand factor level), ante-mortem oxygenation (myelin-associated glycoprotein:proteolipid protein-1 ratio and vascular endothelial growth factor level), Aβ level and plaque load, in precuneus and underlying white matter from 49 AD to 37 control brains. There was reduction in PDGFRB and increased fibrinogen in the precuneus in AD. These changes correlated with reduction in oxygenation and with plaque load. In the underlying white matter, increased fibrinogen correlated with reduced oxygenation, but PDGFRB level was unchanged. The level of platelet-derived growth factor-ββ (PDGF-BB), important for pericyte maintenance, was increased in AD but mainly in the insoluble tissue fraction, correlating with insoluble Aβ level. Loss of the PDGFRB within the precuneus in AD is associated with fibrinogen leakage and reduced oxygenation, and related to fibrillar Aβ accumulation. In contrast, fibrinogen leakage and reduced oxygenation of underlying white matter occur independently of loss of PDGFRB, perhaps secondary to reduced transcortical perfusion.

Cited by papers we hold 14

• The neuroimmune axis of Alzheimer’s disease · 2023
  No notice
• The blood-brain barrier in aging and neurodegeneration · 2022
  No notice
• In vivo Single Cell Optical Ablation of Brain Pericytes · 2022
  Not checked
• Pericyte remodeling is deficient in the aged brain and contributes to impaired capillary flow and structure · 2022
  No notice
• Pathological changes within the cerebral vasculature in Alzheimer’s disease: New perspectives · 2022
  No notice
• The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer’s Disease · 2021
  Not checked
• Cognitive impact of COVID-19: looking beyond the short term · 2020
  No notice
• Tau Protein and Its Role in Blood–Brain Barrier Dysfunction · 2020
  No notice
• Loss of capillary pericytes and the blood–brain barrier in white matter in poststroke and vascular dementias and Alzheimer’s disease · 2020
  No notice
• Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease · 2019
  No notice
• Vascular Dysfunction in Alzheimer’s Disease: A Prelude to the Pathological Process or a Consequence of It? · 2019
  No notice
• Brain expression of the vascular endothelial growth factor gene family in cognitive aging and alzheimer’s disease · 2019
  No notice
• CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology · 2019
  No notice
• Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism · 2018
  Corrected

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.